Absci
Market cap $1.31B 172.7M shares (10-Q, Oct 30, 2026) × $7.58 close Nov 17, 2026
Most recent annual filing: 2026-03-24
- ABS-201 AGA interimDec 2026ABS-201 AGA interim, Dec 2026, major
- ABS-201 AGA toplineEarly 2027ABS-201 AGA topline, Early 2027, thesis-defining
- ABS-201 Endometriosis Ph2 startmid-2027ABS-201 Endometriosis Ph2 start, mid-2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
ABS-101
ABS-301
- Undisclosed indication
ABS-501
- Undisclosed indication
ABS-202
- Undisclosed indication
Technology platforms
Integrated Drug Creation
AI-native antibody drug creation platform combining Origin-1 generative design model with lab-in-the-loop wet lab validation; supports de novo antibody design, multi-parametric lead optimization, and reverse immunology; applicable across oncology, immunology, inflammation, and other therapeutic areas with significant unmet medical need
Origin-1
De novo full-length monoclonal antibody design platform targeting zero-prior epitopes; generates epitope-specific, atomically accurate binders with functional potency; validated against four targets including COL6A3 and AZGP1 by cryo-EM; feeds into Integrated Drug Creation platform
Integrated Drug Creation · AMD
AI-native integrated drug creation platform combining Origin-1 generative design model with lab-in-the-loop rapid validation; supports de novo antibody design, multi-parametric lead optimization, and reverse immunology across oncology, immunology, and inflammation disease areas.
Origin
Generative AI platform for de novo antibody design; enables design of therapeutic candidates against challenging targets including prolactin receptor biology across multiple therapeutic areas
Targets: PRLR
ATLAS
Absci's drug discovery and design platform referenced in forward-looking statements alongside the company's generative AI approach
AbsciDesign
De novo AI antibody design platform using structure and sequence inputs to generate and experimentally validate therapeutic antibody candidates; focus areas include antibody-based therapeutics across immunology, inflammation, and metabolism
Capital (as filed)
- Cash
- $13.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $160M Sep 30, 2026
- Long-term investments
- $44.6M Sep 30, 2026
- Operating cash flow
- −$29.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $174M cash, runway 2H 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-06-24 424B5 · Priced offering 13.5M shares · at $7.41 · $100M gross · 0.0% above the prior close ($7.41, Jun 23, 2026)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-13 UPDATE: Absci (ABSI) - December Is Booked, Endometriosis Slips 🔒 Paid
- 2026-08-12 UPDATE: Absci (ABSI) - The Genetics Slide Nobody Read 🔒 Paid
- 2026-06-24 UPDATE: Absci (ABSI) - Lilly Shows Up, ADAs Don’t 🔒 Paid
- 2026-05-08 UPDATE: Absci (ABSI) - The AI Didn’t Hallucinate (Yet) 🔒 Paid
- 2026-05-04 Absci Corp (ABSI) - Scientific Deep Dive for ABS-101, ABS-201, and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Absci, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-04 Watch Absci Corp (ABSI) - Scientific Deep Dive for ABS-101, ABS-201, and Pipeline Products ABS-201 is a high-risk binary bet on a novel AI-designed antibody mechanism; wait on the sidelines until the Phase 1/2a safety readout in 1H 2026 removes the existential biologic risk before committing capital.
- 2026-05-08 Speculative buy speculative UPDATE: Absci (ABSI) - The AI Didn't Hallucinate (Yet) SAD cohorts completed with clean tolerability and preliminary PK supporting the 2-3 dose/6-month dosing thesis, retiring the most catastrophic immunogenicity risk and warranting a starter position sized like a lottery ticket ahead of Q2 ADA confirmation.
- 2026-06-24 Buy core UPDATE: Absci (ABSI) - Lilly Shows Up, ADAs Don't The 65-day half-life landed in humans, ADAs showed no apparent PK impact, and Eli Lilly anchored a $100M raise at $7.41, retiring the bear case and validating the commercial dosing thesis ahead of the 2H 2026 PoC readout.
- 2026-08-12 Buy core UPDATE: Absci (ABSI) - The Genetics Slide Nobody Read UK Biobank Mendelian randomization data causally implicates PRLR in pattern hair loss, cash runway extended to 2H 2028, and MAD Cohort 3 enrolling on schedule; the -12.5% drop is post-run-up digestion, not a fundamental repricing.
- 2026-11-13 Hold UPDATE: Absci (ABSI) - December Is Booked, Endometriosis Slips Endometriosis Phase 2 slipped to mid-2027, a new shelf signals dilution even on a good December print, and commercial spending is ramping before efficacy evidence; hold through the December 13-week PoC readout but do not chase from the sidelines.
- Long call · opened May 8, 2026 at $5.90 · +28.5% vs XBI +7.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (28)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 20, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026S-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseAbsci Reports Business Updates and Third Quarter 2026 Financial and Operating Resultsvia aggregator→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseAbsci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipelinevia aggregator→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations, other events · EX-99.1→ BD updateQ3 numbers are in, the December PoC readout is weeks away, and ABSI dropped -9.7% on news that actually strengthens the runway thesis — plus a new CCO hire and detailed STORYLINE trial design for endometriosis.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 13, 2026ReleaseAbsci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026via aggregator
- Sep 24, 2026ReleaseAbsci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosisvia aggregator
- Aug 11, 2026ReleaseAbsci Reports Business Updates and Second Quarter 2026 Financial and Operating Resultsvia aggregator
- Aug 11, 20268-KCurrent report: results of operations, other events · EX-99.1BD extracted 1 program update from this document → ABSI pipeline
- Aug 11, 202610-QQuarterly report
- Jul 14, 2026ReleaseAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Jun 24, 2026ReleaseAbsci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investorsvia aggregator
- Jun 24, 2026ReleaseAbsci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)BD extracted 1 program update from this document → ABSI pipeline
- Jun 24, 20268-KCurrent report: other events · EX-99.1
- Jun 24, 20268-KCurrent report: material agreement, other events · EX-99.1
- Jun 24, 2026424B5Prospectus supplement (offering)
- Jun 12, 2026ReleaseMindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discoveryvia aggregator
- Jun 5, 20268-KCurrent report: shareholder vote
- May 20, 2026ReleaseAbsci to Participate in Upcoming Investor Conferences
- May 7, 20268-KCurrent report: results of operations, other events · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Apr 14, 2026SCHEDULE 13D/A13D amendment
- Mar 26, 2026SCHEDULE 13D/A13D amendment
- Mar 24, 20268-KCurrent report: results of operations, other events · EX-99.1
- Mar 24, 202610-KAnnual report
- Mar 6, 20268-KCurrent report: material agreement, officer / director change, Reg FD disclosure · EX-99.1
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Oct 27, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment
- Mar 24, 2026S-8Employee plan registration